Tag: Prescription Drugs
Drug Interaction Checkers Could Have Caught Adverse Events
More than three-quarters of COVID-19-associated drug-drug interactions could have been identified
Single Dose of AZD7442 Prevents Symptomatic or Severe COVID-19
Relative risk reduction of 82.8 percent seen in symptomatic COVID-19 at extended follow-up of median of six months
Adding Tislelizumab to Chemo Slows Advanced Nasopharyngeal Cancer
Progression-free survival prolonged with tislelizumab + chemotherapy versus chemotherapy alone in recurrent/metastatic NPC
NSAIDs May Interfere With Efficacy of Bisphosphonates
No reduction in osteoporotic fracture risk seen among women receiving concomitant clodronate and NSAIDs
Mitapivat Superior to Placebo for Pyruvate Kinase Deficiency
Early, sustained, clinically significant hemoglobin response seen in 40 percent of patients receiving mitapivat versus none in the placebo group
Ivosidenib + Azacitidine Ups Event-Free Survival in IDH1-Mutated AML
Event-free survival significantly longer compared with placebo and azacitidine for newly diagnosed IDH1-mutated AML
Many Medicare Beneficiaries Do Not Fill High-Price Prescriptions
Among beneficiaries without low-income subsidy, noninitiation reported in 30 percent of those with new prescriptions for anticancer drugs
Use of Extrapolation Common in FDA New Drug Approvals
Extrapolation of the findings from pivotal clinical trials to the approved indication most common for disease severity
PDE5 Inhibitors Prescribed for Men on Oral Nitrates for IHD
Among men with ischemic heart disease, coprescription of nitrates and PDE5 inhibitors not linked to increased risk for cardiovascular events
Vijoice Granted First Approval for Treatment of PROS
Real-world data show 27 percent of patients with PIK3CA-related overgrowth spectrum treated with Vijoice had radiological response at 24 weeks
